Stopping Denosumab: What the Rebound-Fracture Evidence Shows About Discontinuation

Denosumab's effect on bone is fully reversible, so stopping it without a follow-on drug lets bone turnover rebound above pretreatment levels within months. In post hoc analyses of the FREEDOM trial and its Extension, vertebral fracture rates rose sharply after discontinuation, and most people who fractured sustained more than one vertebral fracture. That signal, not any doubt about the drug's benefits during treatment, is why professional societies now describe stopping denosumab as a step that needs a plan rather than a simple pause.

Why denosumab is different from a bisphosphonate

Denosumab is a monoclonal antibody that binds RANKL, a signal that osteoclasts (the cells that break down bone) need in order to mature and work. Block that signal and bone resorption falls quickly, bone density rises, and fracture risk drops. The catch is in how the effect ends. Bisphosphonates bind into the bone mineral itself and linger for months or years after the last dose, so their protection tapers slowly. Denosumab does not embed in bone. Once a scheduled dose is missed and the antibody clears, RANKL signaling switches back on and the osteoclast population it had been suppressing returns, often overshooting where it started.

The ECTS position statement in the Journal of Clinical Endocrinology and Metabolism (2021) summarizes the sequence: bone turnover markers climb within a few months after a missed dose, exceed baseline levels, and the bone density gained on treatment is largely lost within roughly one to two years. This is what clinicians mean by rebound. It is less a side effect in the usual sense than the predictable end of a reversible drug's action.

What the FREEDOM Extension analyses actually showed

The most cited evidence comes from Cummings and colleagues, a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its Extension, published in the Journal of Bone and Mineral Research (2018). Among participants who stopped denosumab, the rate of new vertebral fractures rose from about 1.2 per 100 participant-years while on the drug to roughly 7.1 per 100 participant-years after stopping. Put another way, the off-treatment vertebral fracture rate rose to a level close to what was seen in the placebo group, but concentrated into the months after discontinuation.

The more striking finding was the pattern of those fractures. The rate of multiple vertebral fractures went from about 0.4 to 4.2 per 100 participant-years, and among people who fractured after stopping, roughly 61 percent had two or more vertebral fractures. A history of prior vertebral fracture, either before treatment or during the off-treatment period, was associated with higher risk. Because this is a post hoc analysis rather than a trial designed to test discontinuation, the exact numbers deserve caution, and the number of events was small. The direction and the clustering, though, have been consistent enough across the trial data and later case series to be taken seriously.

A 2018 report in CMAJ helped bring the finding to wider clinical attention, describing the roughly sixfold rise in vertebral fracture rate after cessation and the tendency toward several fractures in the same person. Later reviews, including a 2023 synthesis in the Journal of Clinical Medicine, place the typical timing of these rebound-associated vertebral fractures at about eight to sixteen months after the last injection and note that they often present as sudden, severe back pain from several fractured vertebrae rather than a single one.

Why the timing and the pattern matter

Two features make this rebound worth understanding before starting the drug, not only when stopping it. First, the risk is time-limited but front-loaded: it concentrates in the year or so after a dose is missed, which means a delayed or forgotten injection is not a harmless lapse. Second, the multiple-fracture pattern means the clinical stakes of a single missed window can be high, since several vertebral fractures together carry more pain and disability than one.

This is also why the standard advice for stopping other osteoporosis drugs does not transfer. A bisphosphonate can sometimes be paused as a planned drug holiday because the mineral-bound reservoir keeps working. Denosumab has no such reservoir, so there is no true holiday, only a handoff or a cliff.

What guidelines recommend

The ECTS position statement recommends reassessing after about five years of denosumab and, for people who stop, describes giving an antiresorptive such as a bisphosphonate to blunt the rebound in bone turnover rather than simply discontinuing. The guidance referenced in the 2023 review suggests timing that follow-on treatment to roughly six months after the last denosumab injection, before the rebound window opens. Optimal drug choice, timing, and duration are still debated, and the trial evidence for these transition strategies is thinner than the evidence for the rebound itself. What the guidelines share is a single message: the decision to stop denosumab is really a decision about what comes next.

This article is educational and is not medical advice; decisions about starting, continuing, or transitioning off any osteoporosis medication belong to an individual and their own clinician, who can weigh fracture history, bone density, and other risks. The point here is narrower. The FREEDOM Extension data reframed denosumab discontinuation from an afterthought into a step that warrants the same planning as starting the drug, precisely because the mechanism that makes it work so cleanly is the same one that makes stopping it abruptly a measurable risk.